Incidence of Post-denosumab Rebound Hypercalcaemia in Bony-Metastatic Breast Cancer

Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090. https://doi.org/10.1002/(sici)1097-0142(20000301)88:5%3c1082::aid-cncr20%3e3.0.co;2-z

CAS  Article  PubMed  Google Scholar 

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139. https://doi.org/10.1200/JCO.2010.29.7101

CAS  Article  PubMed  Google Scholar 

O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A (2017) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 10(10):CD003474. https://doi.org/10.1002/14651858.CD003474.pub4

Article  PubMed  Google Scholar 

Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10(1):152. https://doi.org/10.3390/jcm10010152

CAS  Article  PubMed Central  Google Scholar 

Camponovo C, Aubry-Rozier B, Lamy O, Gonzalez RE (2020) Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. Osteoporos Int 31(12):2485–2491. https://doi.org/10.1007/s00198-020-05676-7

CAS  Article  PubMed  PubMed Central  Google Scholar 

Stewart AF (2005) Clinical practice. hypercalcemia associated with cancer. N Engl J Med. 352(4):373–379. https://doi.org/10.1056/NEJMcp042806

CAS  Article  PubMed  Google Scholar 

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972–980. https://doi.org/10.1210/jc.2010-1502

CAS  Article  PubMed  Google Scholar 

Wang R, Renouf DA (2022) Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer. Osteoporos Int. https://doi.org/10.1007/s00198-022-06369-z

Article  PubMed  PubMed Central  Google Scholar 

Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, Huang S, Stad RK (2020) Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab 105(3):e255–e264. https://doi.org/10.1210/clinem/dgz095

Article  Google Scholar 

Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K (2020) ESMO guidelines committee bone health in cancer: ESMO clinical practice guidelines. Ann Oncol 31(12):1650–1663. https://doi.org/10.1016/j.annonc.2020.07.019

CAS  Article  PubMed  Google Scholar 

Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD (2020) The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone 138:115478. https://doi.org/10.1016/j.bone.2020.115478

CAS  Article  PubMed  Google Scholar 

Sølling AS, Harsløf T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res 35(10):1858–1870. https://doi.org/10.1002/jbmr.4098

CAS  Article  PubMed  Google Scholar 

Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032–1045. https://doi.org/10.4065/83.9.1032

CAS  Article  PubMed  Google Scholar 

Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San MJ (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43(2):222–229. https://doi.org/10.1016/j.bone.2008.04.007

CAS  Article  PubMed  Google Scholar 

Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O (2020) Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat 179(1):153–159. https://doi.org/10.1007/s10549-019-05458-8

CAS  Article  PubMed  Google Scholar 

Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris AL, Bottini A, Dogliotti L, Angeli A, Berruti A (2008) Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. Br J Cancer 98(11):1753–1758. https://doi.org/10.1038/sj.bjc.6604390

CAS  Article  PubMed  PubMed Central  Google Scholar 

Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D (2007) The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res 27(4A):1853–1862

CAS  PubMed  Google Scholar 

Lumachi F, Santeufemia DA, Del Conte A, Mazza F, Tozzoli R, Chiara GB, Basso SM (2013) Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer. Anticancer Res 33(6):2593–2596

CAS  PubMed  Google Scholar 

Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E (2007) Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178:849–853. https://doi.org/10.1016/j.juro.2007.05.029

CAS  Article  PubMed  Google Scholar 

Sim IW, Borromeo GL, Tsao C, Hardiman R, Hofman MS, Papatziamos Hjelle C, Siddique M, Cook GJR, Seymour JF, Ebeling PR (2020) Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled. Randomized Trial J Clin Oncol 38(26):2971–2980. https://doi.org/10.1200/JCO.19.02192

Article  PubMed  Google Scholar 

Santen RJ (2011) Clinical review: effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 96(2):308–319. https://doi.org/10.1210/jc.2010-1679

CAS  Article  PubMed  Google Scholar 

留言 (0)

沒有登入
gif